Otonomy market cap is $76 m, and annual revenue was $745 k in FY 2018

Otonomy Gross profit (Q3, 2019)-95 K

Otonomy Gross profit margin (Q3, 2019), %(76%)

Otonomy Net income (Q3, 2019)-10 M

Otonomy EBIT (Q3, 2019)-10.1 M

Otonomy Cash, 30-Sept-201916.3 M

Otonomy EV74.6 M

Otonomy revenue was $745 k in FY, 2018 which is a 39.7% year over year decrease from the previous period.

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Revenue | 683.0k | 1.2m | 745.0k |

| 81% | (40%) | |

## Cost of goods sold | 1.7m | 3.1m | 946.0k |

## Gross profit | (981.0k) | (1.9m) | (201.0k) |

| (144%) | (151%) | (27%) |

## R&D expense | 60.7m | 42.7m | 31.8m |

## General and administrative expense | 49.8m | 46.8m | 20.0m |

## Operating expense total | 112.2m | 92.6m | 52.8m |

## EBIT | (111.5m) | (91.4m) | (52.1m) |

| (16322%) | (7395%) | (6987%) |

## Interest expense | 4.0k | ||

## Interest income | 899.0k | 1.3m | 1.7m |

## Net Income | (110.6m) | (90.1m) | (50.4m) |

- Source: SEC Filings

USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k | 192.0k | 190.0k | 125.0k |

## Cost of goods sold | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k | 213.0k | 203.0k | 220.0k |

## Gross profit | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) | (21.0k) | (13.0k) | (95.0k) |

| (29%) | (22%) | (3%) | 10% | (96%) | (43%) | (11%) | (7%) | (76%) |

## R&D expense | 13.2m | 12.7m | 10.8m | 5.7m | 8.2m | 8.3m | 8.8m | 8.9m | 8.1m |

## General and administrative expense | 14.1m | 10.7m | 10.5m | 6.2m | 5.6m | 4.7m | 3.3m | 2.9m | 1.9m |

## Operating expense total | 27.7m | 23.9m | 21.6m | 12.1m | 14.1m | 13.1m | 12.3m | 11.8m | 10.0m |

## EBIT | (27.4m) | (23.5m) | (21.3m) | (11.8m) | (14.0m) | (13.0m) | (12.1m) | (11.8m) | (10.1m) |

| (7649%) | (7218%) | (7559%) | (3913%) | (11351%) | (11505%) | (6299%) | (6219%) | (8044%) |

## Interest expense | 391.0k | ||||||||

## Interest income | 304.0k | 311.0k | 319.0k | 354.0k | 409.0k | 455.0k | 501.0k | 489.0k | 419.0k |

## Net Income | (27.1m) | (23.2m) | (21.0m) | (11.4m) | (13.6m) | (12.5m) | (12.0m) | (11.7m) | (10.0m) |

- Source: SEC Filings

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Cash | 24.2m | 18.5m | 33.6m |

## Accounts Receivable | 91.0k | 107.0k | 108.0k |

## Inventories | 1.4m | 6.0k | |

## Current Assets | 202.2m | 122.4m | 100.1m |

## PP&E | 5.0m | 4.7m | 4.0m |

## Total Assets | 208.6m | 128.4m | 105.0m |

## Accounts Payable | 1.3m | 961.0k | 1.0m |

## Current Liabilities | 15.2m | 8.2m | 7.5m |

## Long-term debt | 14.8m | ||

## Total Debt | 14.8m | ||

## Total Liabilities | 15.9m | 11.1m | 25.3m |

## Additional Paid-in Capital | 467.5m | 482.2m | 494.9m |

## Retained Earnings | (274.7m) | (364.8m) | (415.2m) |

## Total Equity | 192.7m | 117.3m | 79.7m |

## Debt to Equity Ratio | 0.2 x | ||

## Debt to Assets Ratio | 0.1 x | ||

## Financial Leverage | 1.1 x | 1.1 x | 1.3 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Net Income | (110.6m) | (90.1m) | (50.4m) |

## Depreciation and Amortization | 708.0k | 1.3m | 1.2m |

## Accounts Receivable | (91.0k) | (16.0k) | (1.0k) |

## Inventories | (1.4m) | 153.0k | |

## Accounts Payable | (2.2m) | (398.0k) | 68.0k |

## Cash From Operating Activities | (94.3m) | (75.3m) | (38.4m) |

## Purchases of PP&E | (2.5m) | (1.3m) | (496.0k) |

## Cash From Investing Activities | (149.4m) | 69.0m | 38.0m |

## Cash From Financing Activities | 109.2m | 1.1m | 15.2m |

## Interest Paid | 4.0k |

- Source: SEC Filings

USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (27.1m) | (71.3m) | (11.4m) | (25.0m) | (37.5m) | (12.0m) | (23.7m) | (33.7m) | |

## Depreciation and Amortization | 923.0k | 295.0k | 594.0k | 892.0k | 276.0k | 565.0k | 854.0k | ||

## Accounts Receivable | 178.0k | 76.0k | (35.0k) | (26.0k) | 93.0k | 62.0k | 94.0k | 40.0k | 75.0k |

## Inventories | 1.2m | 1.2m | 197.0k | 6.0k | |||||

## Accounts Payable | 212.0k | 1.3m | 138.0k | 1.5m | (184.0k) | 321.0k | 123.0k | 837.0k | (90.0k) |

## Cash From Operating Activities | (60.9m) | (9.8m) | (20.1m) | (28.1m) | (10.5m) | (19.3m) | (29.6m) | ||

## Purchases of PP&E | (844.0k) | (74.0k) | (343.0k) | (463.0k) | (36.0k) | (153.0k) | (297.0k) | ||

## Cash From Investing Activities | 53.6m | 14.5m | 20.4m | 30.3m | (6.8m) | (2.3m) | 12.2m | ||

## Cash From Financing Activities | 549.0k | 32.0k | 229.0k | 229.0k | (52.0k) | 69.0k | 71.0k | ||

## Net Change in Cash | (6.8m) | 4.8m | 570.0k | 2.5m | (17.4m) | (21.5m) | (17.4m) | ||

## Interest Paid | 347.0k | 698.0k | 1.0m |

- Source: SEC Filings

USD | Y, 2019 |
---|---|

## EV/EBIT | -7.4 x |

## EV/CFO | -2.5 x |

## Debt/Equity | 0.3 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 1.8 x |

FY, 2016 | |
---|---|

## Patents Issued | 88 |

## Patents Pending | 115 |

## Phase I Trials Products | 1 |

## Phase II Trials Products | 2 |

## Phase III Trials Products | 2 |

## Preclinical Phase Products | 1 |

## Products | 1 |

- Source: SEC Filings